NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

TerminatedPhase 1

Sponsor: AstraZeneca

Conditions: Solid Tumors

Interventions: MEDI9253, Durvalumab

Countries: United States, France

Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.

Eligibility overview

Sex: ALL

Age: 18 Years to 101 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Participant must be at least 18 years old at signing of informed consent.
2. Body weight \> 35 kg at screening.

Exclusion Criteria:

1 Primary central nervous system (CNS) disease is excluded, as well as untreated or uncontrolled metastatic CNS involvement, leptomeningeal disease, or cord compression.

NOTE: CNS disease that has been treated and stable/controlled for at least 3 months is permitted. Participants with CNS disease controlled via systemic steroids are not permitted.

Locations (8)

St Louis, Missouri, United States
Buffalo, New York, United States
New York, New York, United States
New York, New York, United States
Pittsburgh, Pennsylvania, United States
Bordeaux, France
Toulouse, France
Villejuif, France